GIP as a therapeutic target in diabetes and obesity: Insight from incretin co-agonists
GLP-1 Receptor Pathway - Reduces hunger drive centrally (hypothalamus, brainstem) - Decreases the reward value of food (mesolimbic system) - Enhances glucose-dependent insulin secretion - Slows gastric emptying Amylin Receptor Pathway - Induces satiety through the area postrema and NTS - Activates POMC neurons (pro-satiety) and suppresses NPY/AgRP neurons (pro-hunger) in the arcuate nucleus - Additional gastric emptying delay through distinct neural circuits - Suppresses post-prandial glucagon secretion - May contribute to leptin resensitization The combination of these two pathways produces what researchers describe as broader modulation of neuroendocrine appetite control meaning amycretin hits more of the biological switches that drive eating behavior than a GLP-1-only drug can reach
IBS is difficult to treat, with few practical therapy approaches available despite its high incidence, financial and health costs, and severity (3)
For instance, GLP-1RAs can improve the levels of insulin, regulate the levels of sex hormone, improve the blood lipid profile, increase the levels of adiponectin, regulate autophagy, inhibit the production of liver glucose, reduce the liver fat content, as well as reduce the levels of plasma liver enzymes and liver steatosis
The impact of two types of mannogalactoglucan polysaccharides (WPLE-N-2 and WPLE-A0.5-2) was evaluated on the cellular immune response in mice carrying Sarcoma 180 (S-180) [54]
Measurement of bound sulfane sulfur A whole brain homogenates were prepared with 9 volumes of ice-cold buffer consisting of 10 mM potassium phosphate (pH 7.4), 1% TritonX-100, 10 mM hydroxylamine, which was used to suppress the activity of PLP-dependent enzymes involved in enzymatic H 2 S production, and protease inhibitor cocktail complete (Roche Diagnostics, Mannheim, Germany) using a Potter type glass homogenizer with a Teflon pestle (1,500 rpm, 10 strokes)